Healthcare
enGene Holdings Inc. Warrants(ENGNW)
Live Price
Offline$2.23
+0.00% today
1Y Change
+189.99%
Window
Jun 25, 2025 β Jun 18, 2026
- Market Cap
- $400.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -56.8%
- Dividend Yield
- 0.0%
Coverage: 209 bars Β· Jun 25, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
enGene Holdings Inc. Warrants (ENGNW) is a Healthcare stock with a market cap of $400.00M and listed on NASDAQ. The stock last traded around $2.23 and up 190.0% across the available one-year price window (Jun 25, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -56.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -56.8%, free cash flow -104.7% with operating margin 0.0% and ROIC -40.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ENGNW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -56.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -14.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 12, 2026 | β | +0.0% | β | β |
2026 Mar 9, 2026 | +21.4% | -7.7% | -31.4% | -31.4% |
2025 Dec 22, 2025 | +578.0% | +7.1% | +3.4% | +2.1% |
Benchmark Edge
ENGNW vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ENGNW
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ENGNW Max Drawdown
-64.19%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ENGNW and SPY.
Company Overview
enGene Holdings Inc. Warrants
NASDAQ Capital Market
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-GuΓ©rin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
- Leadership
- Ronald H. W. Cooper
- IPO Date
- Feb 1, 2022
- Employees
- 56
- Street Address
- 4868 Rue Levy
- Mailing
- Montreal, QC, H4S 1Z9
- Region
- Montreal, QC, CA
- Reporting Currency
- USD
- Investor Line
- 514 332 4888
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 1.9
Growth
- Revenue
- 0.0%
- EPS
- -56.8%
- Free Cash Flow
- -104.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -55.8%
- ROIC
- -40.5%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 11.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.